Endpoints News
Endeavor’s chronic lung disease win Read in browser
Endpoints News
Thank you for reading, Test Researcher!
basic
UPGRADE
M T W Thu F
8 October, 2026
$142 billion in 340B medicine markups
Nearly 60% of 340B spending is driven by medicine markups. The federal 340B program is now a $244B behemoth yet there is little oversight or accountability, unlike most federal programs. Learn more.
sponsored by PhRMA
presented by ALTASCIENCES
The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy
top stories
1. Long ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma
2. Endeavor notches major mid-stage trial win, says IPF drug can reverse disease
3. Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
4.
news briefing
Ono to pay Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya vaccine
5. Argenx's study flop in Sjögren's overshadows a win in celiac disease
6. Roche does fourth China deal since August, teaming with Defand on degraders
7. Zuckerberg's Biohub expands virtual cell effort to $1.8B, looping in Isomorphic, Meta, Google
more stories
• 
Karen Weintraub
.

The serious pregnancy condition preeclampsia has long been overlooked by drugmakers, though it accounts for half a million fetal deaths and lifelong complications. The WHO issued a 94-page report on Thursday, and biopharma is starting to tune in, Kyle LaHucik reports.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Kyle LaHucik

A preg­nan­cy-re­lat­ed hy­per­ten­sion dis­or­der that im­pacts mil­lions of moth­ers and new­borns each year is get­ting more at­ten­tion from the top lev­els of pub­lic health or­ga­ni­za­tions...

Read the full story
John Hood, Endeavor BioMedicines CEO
2
by Lei Lei Wu

En­deav­or Bio­Med­i­cines saidits treat­ment for a chron­ic lung dis­ease suc­ceed­ed in a mid-stage test, claim­ing the drug had the po­ten­tial to re­verse the course...

Read the full story
3
by Max Gelman

Zealand Phar­ma and Roche rolled out some mid-stage da­ta for their amylin drug in obe­si­ty and di­a­betes, hop­ing to com­pete with Eli Lil­ly.

In a...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about ADC Ther­a­peu­tics, Atri­um Ther­a­peu­tics, Bris­tol My­ers, No­var­tis and Pfiz­er.

Bio­haven part­ners with Ono: Tokyo-based Ono Phar­ma­ceu­ti­cal has agreedto pay Bio­haven $80...

Read the full story
5
by Ayisha Sharma

Ar­genx on Thurs­day re­port­ed one suc­cess and one set­back in its au­toim­mune dis­ease pipeline, send­ing its shares tum­bling.

The Bel­gian-Dutch phar­ma saidit is shut­ter­ing...

Read the full story
6
by Kyle LaHucik